Pancreatic Cancer Research

ResearcherNebraska Medical CenterNo recent work listed

Chi H. Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7279-0473; OpenAlex author ID A5070146210. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
62
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 5 papers · 2018: none · 2019: 4 papers · 2020: 6 papers · 2021: 3 papers · 2022: 5 papers

Papers 26

  1. An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2021.12.018↗
  2. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. Co-author DOI 10.1016/j.ebiom.2021.103772↗
  3. Compute Tomography Radiomics Analysis on Whole Pancreas Between Healthy Individual and Pancreatic Ductal Adenocarcinoma Patients: Uncertainty Analysis and Pred… First author DOI 10.1177/15330338221126869↗
  4. Association of facility type with overall survival in patients with nonsurgically managed pancreatic cancer. Last author DOI 10.2217/fon-2021-0986↗
  5. Using Quantitative Imaging for Personalized Medicine in Pancreatic Cancer: A Review of Radiomics and Deep Learning Applications. Co-author DOI 10.3390/cancers14071654↗
  6. The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change? Last author DOI 10.1016/j.ctro.2021.04.002↗
  7. Effects of interobserver and interdisciplinary segmentation variabilities on CT-based radiomics for pancreatic cancer. Co-author DOI 10.1038/s41598-021-95152-x↗
  8. SUMO Modification of PAF1/PD2 Enables PML Interaction and Promotes Radiation Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1128/mcb.00135-21↗
  9. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. Last author DOI 10.1016/j.ctro.2020.06.003↗
  10. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis. Last author DOI 10.1186/s12885-020-07016-8↗
  11. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective anal… Last author DOI 10.1186/s13014-020-01569-5↗
  12. Correction: Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation. Co-author DOI 10.18632/oncotarget.27450↗
  13. The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National… Last author DOI 10.3389/fonc.2020.01518↗
  14. Radiomics-Based Outcome Prediction for Pancreatic Cancer Following Stereotactic Body Radiotherapy. Co-author DOI 10.3390/cancers12041051↗
  15. Incidence and Patterns of Locoregional Failure After Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.prro.2018.06.006↗
  16. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Co-author DOI 10.1016/j.radonc.2018.11.002↗
  17. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic A… Co-author DOI 10.1097/coc.0000000000000599↗
  18. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced panc… Last author DOI 10.1186/s12885-019-6220-1↗
  19. Biological determinants of radioresistance and their remediation in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2017.02.003↗
  20. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospe… Last author DOI 10.1016/j.radonc.2016.12.030↗
  21. MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-1151↗
  22. Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial. Last author DOI 10.1186/s13014-017-0798-8↗
  23. When It Comes to Elderly or Poor Performance Status Patients With Pancreatic Adenocarcinoma, Stereotactic Body Radiation Therapy May Be a Better Option. Co-author DOI 10.1200/jop.2017.022079↗
  24. Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications. Last author DOI 10.1097/coc.0000000000000278↗
  25. Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation. Co-author DOI 10.18632/oncotarget.2500↗
  26. Marital status and survival in pancreatic cancer patients: a SEER based analysis. Co-author DOI 10.1371/journal.pone.0021052↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael J. Baine · 13 shared papers, 2011–2022 · strength 1.70
  2. Saber Amin · 5 shared papers, 2020–2022 · strength 0.88
  3. Jane L. Meza · 6 shared papers, 2019–2020 · strength 0.79
  4. Surinder K. Batra · 6 shared papers, 2011–2022 · strength 0.48
  5. Michael Anthony Hollingsworth · 4 shared papers, 2019–2022 · strength 0.46
  6. Dandan Zheng · 4 shared papers, 2017–2022 · strength 0.45
  7. Bradley Norman Reames · 3 shared papers, 2021–2022 · strength 0.44
  8. Vivek Verma · 5 shared papers, 2016–2019 · strength 0.43
  9. Josiah McAllister · 2 shared papers, 2020–2022 · strength 0.36
  10. Michel M. Ouellette · 4 shared papers, 2014–2022 · strength 0.33
  11. Lynette M. Smith · 2 shared papers, 2022 · strength 0.29
  12. Jeffrey Wong · 2 shared papers, 2021–2022 · strength 0.29
  13. Parthasarathy Seshacharyulu · 3 shared papers, 2017–2022 · strength 0.29
  14. Jean L. Grem · 3 shared papers, 2019–2022 · strength 0.28
  15. Chandrakanth Are · 3 shared papers, 2017–2019 · strength 0.24
  16. Ying Yan · 3 shared papers, 2014–2020 · strength 0.22
  17. Sushil Kumar · 2 shared papers, 2021–2022 · strength 0.22
  18. Rama Krishna Nimmakayala · 2 shared papers, 2021–2022 · strength 0.22
  19. Moorthy Palanimuthu Ponnusamy · 2 shared papers, 2021–2022 · strength 0.22
  20. Lyudmyla Derby Berim · 2 shared papers, 2019–2022 · strength 0.19
  21. Chunmeng Zhang · 1 shared paper, 2022 · strength 0.19
  22. Sukhwinder Kaur · 2 shared papers, 2017–2022 · strength 0.18
  23. Maneesh Jain · 2 shared papers, 2017–2022 · strength 0.18
  24. Shuo Wang · 1 shared paper, 2022 · strength 0.16
  25. Chang Liu · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.